View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 31, 2019

Late-stage SMA pipeline could threaten Biogen’s Spinraza

Spinal Muscular Atrophy (SMA) is a disease caused by a defective SMN gene, which leads to a lack of survival motor neuron (SMN) protein, which is important for the development and maintenance of motor neurons.

By GlobalData Healthcare

Spinal Muscular Atrophy (SMA) is a disease caused by a defective SMN gene, which leads to a lack of survival motor neuron (SMN) protein, which is important for the development and maintenance of motor neurons. The disease causes motor neuron degeneration in the spinal cord and brainstem. The rarity of the disease has meant that the rate of drug development in this field has been slow. According to GlobalData’s Pharma Intelligence Center, there are currently 10 products in pipeline development (Phases I–III). However, treatment options for SMA are expected to witness a dynamic growth in the future due to expected new product approvals, such as a pioneering gene therapy by AveXis, a subsidiary of Novartis, which is anticipated to obtain approval in 2019.

Various strategies adopted by different pipeline products in Phase III hold the potential to pose a considerable threat to the only marketed product currently available for the treatment of SMA, Biogen’s Spinraza (nusinersen). Spinraza is a disease-modifying therapy based on antisense oligonucleotide technology that is administered via an intrathecal route with periodical dosing regimens. In contrast, AveXis’ Zolgensma (onasemnogene abeparvovec-xxxx), a gene therapy product, holds promise as a curative treatment that requires a one-time infusion. Zolgensma is currently undergoing a priority review with the FDA and a decision on the US market approval is expected in early 2019. Similar decisions for the European and Japanese regions are also expected during the same timeframe. Roche’s risdiplam and Novartis’ branaplam, both of which are currently in Phase III development, are proposed to work as survival motor neuron 2 (SMN2)-splicing modifiers. These therapies are designed to modulate the splicing of SMN2 to increase the levels of functional proteins; this mechanism of action is understood to be similar to that of Spinraza.

Given the historical rate of drug development in this field, pharmaceutical companies are keen to develop drugs that can treat this rare disease and help patients improve their quality of life. In theory, gene therapy is the most promising concept in terms of curing a disease. However, it is an evolving area and the long-term effects of such therapies need to be better understood, as these factors may be points of concern for regulatory agencies. The therapy’s potential to cure the disease also means that a high price tag can be expected, which will influence the wider market acceptance of the drug.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology